New combo aims to free ITP patients from long-term medication
NCT ID NCT07400250
First seen Feb 15, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study tests whether combining two drugs—orelabrutinib and romiplostim—can help adults with chronic immune thrombocytopenia (ITP) maintain safe platelet levels and eventually stop other treatments. About 28 participants who have already tried at least one standard therapy will receive the combination for 24 weeks, with follow-up to 56 weeks. The goal is to see if this approach leads to lasting remission without the need for ongoing medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100010, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.